Dapagliflozin
- Generic Name
- Dapagliflozin
- Brand Names
- Edistride, Farxiga, Forxiga, Qtern, Qternmet, Xigduo, Dapagliflozin Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO6
- CAS Number
- 461432-26-8
- Unique Ingredient Identifier
- 1ULL0QJ8UC
- Background
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tubule of the nephron and causing glycosur...
- Indication
Dapagliflozin is indicated as an adjunct treatment to improve glycemic control in adult patients with type 2 diabetes mellitus along with diet and exercise.For patients with chronic kidney disease at risk of progression, dapagliflozin in used to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and
...
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate, Hospitalization due to cardiac failure
- Associated Therapies
- -
A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT06639087
- Locations
- 🇸🇪
Research Site, Mölndal, Sweden
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients with a ST-segment Elevation Myocardial Infarction
- Conditions
- Interventions
- First Posted Date
- 2024-09-30
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hospital Clinic of Barcelona
- Target Recruit Count
- 54
- Registration Number
- NCT06619600
- Locations
- 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain
🇪🇸Hospital Clinic of Barcelona, Barcelona, Catalonia, Spain
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT06610526
- Locations
- 🇨🇳
Research Site, Xian, China
Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Target Recruit Count
- 31
- Registration Number
- NCT06578520
- Locations
- 🇪🇸
Hospital Clínico Universitario de Valencia, Valencia, Spain
Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Future University in Egypt
- Target Recruit Count
- 70
- Registration Number
- NCT06576375
- Locations
- 🇪🇬
October 6 University Hospital, Giza, Egypt
DYNAMic Renal Assessment: NOvel Methods to Assess KIDNEY Functional Reserve
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- King's College Hospital NHS Trust
- Target Recruit Count
- 44
- Registration Number
- NCT06572215
- Locations
- 🇬🇧
King's College Hospital, London, United Kingdom
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-08-01
- Target Recruit Count
- 54
- Registration Number
- NCT06532682
- Locations
- 🇨🇳
Nanjing Medical University First Affiliated Hospital, Nanjing, Jiangsu, China
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 264
- Registration Number
- NCT06528405
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
DapagliFLOzin in Renal AL Amyloidosis (FLORAL)
- First Posted Date
- 2024-05-17
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Jeffrey Zonder
- Target Recruit Count
- 20
- Registration Number
- NCT06420167
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Conditions
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- HighTide Biopharma Pty Ltd
- Target Recruit Count
- 418
- Registration Number
- NCT06415773
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
🇨🇳Binzhou Medical University Hospital, Binzhou, China
🇨🇳The Second Norman Bethune Hospital of Jilin University, Changchun, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.